The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy
Journal of the American Society of Nephrology · 2025-04 · 36 (4) · 657-667
DOI: 10.1681/asn.0000000538 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 26.10.2024. Verfasst von Hiddo J L Heerspink und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biocity Biopharmaceuticals.
Abstract (Originalsprache)
Key Points Patients with IgA nephropathy and significant proteinuria are at high risk of progressive kidney function loss and kidney failure. We report the results of a clinical trial assessing the selective endothelin receptor antagonist SC0062 for the treatment of IgA nephropathy. SC0062 led to clinically meaningful improvements in proteinuria and did not increase risk of peripheral edema at higher doses.
Background
Endothelin receptor type A activation contributes to kidney injury in patients with IgA nephropathy. SC0062 is a novel selective endothelin receptor type A antagonist. We report the results of a phase 2 dose-finding trial to characterize the efficacy and safety of SC0062 in patients with IgA nephropathy.
Methods
We conducted a randomized, placebo-controlled, double-blind, clinical trial in adults with biopsy-proven IgA nephropathy and eGFR ≥30 ml/min per 1.73 m 2 with urine protein-creatinine ratio (UPCR) ≥0.75 g/g or proteinuria ≥1 g/24 hour despite using maximum tolerated doses of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Patients were randomized 1:1:1:1 to 24-week treatment with SC0062 5, 10, and 20 mg or matching placebo once daily. The primary efficacy outcome was percent change from baseline in UPCR in 24-hour urine samples after 12 weeks of treatment. Secondary end points included changes in eGFR. Safety outcomes including treatment-emergent adverse events and serious adverse events were recorded.
Results
Overall, 131 patients (mean age 42 years [SD 11]; mean eGFR 72 ml/min per 1.73 m 2 [SD 24] and median 24-hour UPCR 1.2 g/g [25th–75th percentile, 0.9–1.5 g/g]) were randomized to placebo ( n =34) or SC0062 5 mg ( n =33), 10 mg ( n =32), or 20 mg ( n =32). All SC0062 doses reduced UPCR versus placebo throughout treatment. At week 12, placebo-corrected geometric mean changes (95% confidence interval) from baseline in UPCR with SC0062 5, 10, and 20 mg were−27.6% (−43.0 to −8.2), −20.5% (−37.4 to 1.0), and −38.1% (−51.4 to −21.0), respectively, and at week 24 they were−22.4% (−42.2 to 4.3), −30.9% (−48.6 to −7.0), and −51.6% (−64.2 to −34.6), respectively. No differences in eGFR were observed among treatment groups. The proportion of participants with treatment-emergent adverse events or serious adverse events was balanced among treatment groups. Peripheral edema was reported by two (6%), one (3%), one (3%) participants in the 5, 10, and 20 mg SC0062-treated groups, respectively, compared with five (15%) in the placebo group.
Conclusions
In patients with IgA nephropathy, SC0062 reduced proteinuria and did not increase risk of peripheral edema. Clinical Trial registry name and registration number: A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of CKD, NCT05687890. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2024_10_26_KTS_October2024.mp3
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- The George Institute for Global Health, Sydney, New South Wales, Australia.
- Kidney Disease Center, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
- National Key Clinical Department of Kidney Diseases, Hangzhou, China.
- Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, China.
- Department of Nephrology, General Hospital of Northern Theater Command, Shenyang, China.
ORCID-Profile: Hiddo J L Heerspink, Xiaoying Du, Bin Liu, Jianxin Wan, Rong Wang, Hong Cheng, Yongjiang Hei, Bo Zhou, Liqin Zhang, Jianghua Chen
Förderung
- Biocity Biopharmaceuticals
Zitieren
APA
Heerspink, H. J. L., Du, X., Xu, Y., Zhang, Y., Liu, B., Bi, G., Xu, C., Luo, Q., Wu, H., Wan, J., Cao, L., Wang, R., Fan, Q., Cheng, H., Xu, L., Huang, J., Zhong, A., Peng, Q., Hei, Y., …, & Chen, J. (2025). The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy. Journal of the American Society of Nephrology, 36(4), 657-667. https://doi.org/10.1681/asn.0000000538
Vancouver
Heerspink HJL, Du X, Xu Y, Zhang Y, Liu B, Bi G, et al. The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy. Journal of the American Society of Nephrology. 2025;36(4):657-667. doi:10.1681/asn.0000000538
BibTeX
@article{Heerspink2025,
author = {Heerspink, Hiddo J L and Du, Xiaoying and Xu, Yan and Zhang, Yanning and Liu, Bin and Bi, Guangyu and Xu, Chengyun and Luo, Qun and Wu, Henglan and Wan, Jianxin and Cao, Liou and Wang, Rong and Fan, Qiuling and Cheng, Hong and Xu, Lixia and Huang, Jiyi and Zhong, Aimin and Peng, Qingfeng and Hei, Yongjiang and Wang, Yiwei and Zhou, Bo and Zhang, Liqin and Chen, Jianghua},
title = {The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy},
journal = {Journal of the American Society of Nephrology},
year = {2025},
volume = {36},
number = {4},
pages = {657--667},
doi = {10.1681/asn.0000000538}
}
EUVIMED